The current ALINA trial focused on the EML4-ALK fusion protein second-generation drug alectinib, which enrolled 257 patients with ALK-positive NSCLC in stage IB-IIIA (N2) (7th edition AJCC staging), and divided the patients into two groups: 130 in the oral alectinib group and 127 in the platinum chemotherapy group, which ultimately indicated that, for pN2 stage The study concluded that for patients with pN2 stage ALK-positive NSCLC, alectinib significantly improved disease-free survival (69). The gene discussed is ALK; the disease is non-small cell lung carcinoma.